<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03829566</url>
  </required_header>
  <id_info>
    <org_study_id>DIAD.ATTEND.2018</org_study_id>
    <nct_id>NCT03829566</nct_id>
  </id_info>
  <brief_title>Autologous Transplant To End NMO Spectrum Disorder</brief_title>
  <acronym>ATTEND</acronym>
  <official_title>Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to treat your disease with an autologous stem cell transplant using a&#xD;
      regimen of immune suppressant drugs and chemotherapy to reset your immune system and to&#xD;
      determine if your disease will go into long-term remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The autologous stem cell transplant used in this research study is an investigational&#xD;
      procedure that uses cyclophosphamide (chemotherapy), rabbit antithymocyte globulin (rATG) (a&#xD;
      protein that kills the immune cells that are thought to be causing your disease), rituximab&#xD;
      (a biologic drug that targets B cells of your immune system), and intravenous immunoglobulin&#xD;
      (IVIg) (pooled IgG antibodies from plasma donors with immunomodulatory and anti-inflammatory&#xD;
      effects), followed by return of your own previously collected blood stem cells (autologous&#xD;
      stem cell transplant). One day of plasmapheresis will also be performed the day prior to&#xD;
      admission for stem cell transplant to remove disease-causing antibodies. The ability of this&#xD;
      experimental treatment to stop relapses and progression (worsening) of your NMOSD will be&#xD;
      assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Discontinued by Investigator&#xD;
  </why_stopped>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">November 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease progression defined as: 1.0-point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least six months apart and not due to a non-NMO disease process. The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse defined as: Acute neurologic deterioration occurring after engraftment and lasting more than 24 hours, accompanied by objective worsening on neurological examination that are documented by a neurologist and not explained by fever, infection, stress, heat, drugs or related pseudo-exacerbation. Supportive confirmation by enhancement on MRI is preferred but not mandatory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) Improvement</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. Improvement in EDSS is defined by both a 0.5 or 1.0 points sustained for more than 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scripps Neurological Rating Scale (NRS) Improvement</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>The NRS scale ranges from 0 to 100 in 1 point increments that represent lower levels of disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of Life</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Measured using the short form (SF)-36 health survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paced Auditory Serial Addition Test (PASAT) Improvement</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Improvement measured with the 2&quot; and 3&quot; versions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulation Index Improvement</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>The subject's walk of 25 feet is timed and a score from 0 to 10 is assigned based on their walk/gait and/or assistance required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9 Hole Peg Test (9-HPT) Improvement</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>The 9-HPT is a brief, standardized, quantitative test of upper extremity function. Both the dominant and non-dominant hands are tested twice, with the total time to complete the task each time recorded and then averaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NMO IgG (aquaporin-4) Antibody Titer</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>Evaluation of the antibody titer, looking for a change from positive to negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Visual Acuity</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
    <description>A visual acuity test is an eye exam that checks how well one sees the details of a letter or symbol from a specific distance.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Neuromyelitis Optica</condition>
  <condition>Devic's Disease</condition>
  <condition>NMO Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>A medication used as chemotherapy and to suppress the immune system</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rATG</intervention_name>
    <description>A rabbit polyclonal antibody to lymphocytes</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>Anti-Thymocyte Globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>A corticosteroid medication used to suppress the immune system and decrease inflammation</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Solu-Medrol</other_name>
    <other_name>Depo-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Filgrastim</other_name>
    <other_name>Granix</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IVIg</intervention_name>
    <description>Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Bivigam</other_name>
    <other_name>Carimune Nanofiltered (NF)</other_name>
    <other_name>Gammagard</other_name>
    <other_name>Privigen</other_name>
    <other_name>Octagam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cells</intervention_name>
    <description>Infusion of patient's own stem cells</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 - 65 years old at the time of pre-transplant evaluation&#xD;
&#xD;
          2. An established diagnosis of NMOSD (with or without aquaporin 4 (AQP4)-IgG antibody)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under age of 18 or over age of 65&#xD;
&#xD;
          2. Prisoners&#xD;
&#xD;
          3. Psychiatric illness or mental deficiency making compliance with treatment or informed&#xD;
             consent impossible, or any adult who is unable to consent (for adults cognitively&#xD;
             impaired due to disease, consent may be obtained from the closest living relative).&#xD;
&#xD;
          4. Paraplegia or quadriplegia (must be able to use a walker if even for only a few feet)&#xD;
&#xD;
          5. Extensive subcortical white matter lesions&#xD;
&#xD;
          6. Uncontrolled diabetes mellitus or any other illness that in the opinion of the&#xD;
             investigators would jeopardize the ability of the patient to tolerate aggressive&#xD;
             treatment&#xD;
&#xD;
          7. Myocardial infarction within the last 12 months. If longer than 12 months, must pass a&#xD;
             dobutamine stress test and be cleared by cardiology.&#xD;
&#xD;
          8. Active systemic lupus erythematous, Sjogren's, myasthenia gravis, or another&#xD;
             autoimmune disease&#xD;
&#xD;
          9. Sickle cell disease, sickle cell disease, or coagulopathy&#xD;
&#xD;
         10. Prior history of malignancy that required any radiotherapy, chemotherapy, or&#xD;
             biological therapy&#xD;
&#xD;
         11. Positive pregnancy test, inability or unable to pursue effective means of birth&#xD;
             control, or failure to willingly accept or comprehend irreversible sterility as a side&#xD;
             effect of therapy&#xD;
&#xD;
         12. Women who are breastfeeding&#xD;
&#xD;
         13. Untreated life-threatening cardiac arrhythmia on electrocardiogram (EKG) or 24-hour&#xD;
             holter&#xD;
&#xD;
         14. Left ventricular ejection fraction (LVEF) &lt;50%&#xD;
&#xD;
         15. Tiffeneau-Pinelli index (FEV1/FVC) &lt;70% of predicted after bronchodilator therapy (if&#xD;
             necessary), or diffusing capacity of lung for carbon monoxide (DLCO) hemoglobin&#xD;
             corrected &lt;70 % predicted&#xD;
&#xD;
         16. Serum creatinine &gt;2.0 mg/dl&#xD;
&#xD;
         17. Liver cirrhosis, transaminases &gt;2x of normal limits, or bilirubin &gt;2.0 mg/dl unless&#xD;
             due to Gilbert's disease&#xD;
&#xD;
         18. Major hematological abnormalities such as platelet count &lt; 100,000/μl or absolute&#xD;
             neutrophil count (ANC) &lt; 1000/μl&#xD;
&#xD;
         19. Active infection except asymptomatic bacteriuria&#xD;
&#xD;
         20. Presence of metallic objects implanted in the body that would preclude the ability of&#xD;
             the patient to safely have magnetic resonance imaging (MRI) exams&#xD;
&#xD;
         21. Known hypersensitivity to mouse, rabbit, or E. coli derived proteins&#xD;
&#xD;
         22. Human immunodeficiency virus (HIV) positive&#xD;
&#xD;
         23. Hepatitis B or C positive&#xD;
&#xD;
         24. Use of natalizumab (Tysabri) within the previous six months&#xD;
&#xD;
         25. Use of fingolimod (Gilenya) within the previous three months&#xD;
&#xD;
         26. Use of dimethyl fumarate (Tecfidera) within the previous three months&#xD;
&#xD;
         27. Use of teriflunomide (Aubagio) unless cleared from the body (plasma concentration&#xD;
             &lt;0.02mcg/ml) following elimination from the body with cholestyramine 8g three times a&#xD;
             day for 11 days&#xD;
&#xD;
         28. Use of alemtuzumab (Lemtrada/Campath) within previous 12 months&#xD;
&#xD;
         29. Use of rituximab (Rituxan) or ocrelizumab (Ocrevus) within previous six months&#xD;
&#xD;
         30. Prior treatment with mitoxantrone (Novantrone)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University, Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 1, 2019</study_first_submitted>
  <study_first_submitted_qc>February 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Autologous Stem Cell Transplantation</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03829566
org study id: DIAD.ATTEND.2018
nct id: NCT03829566
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This study is designed to treat your disease with an autologous stem cell transplant using a
      regimen of immune suppressant drugs and chemotherapy to reset your immune system and to
      determine if your disease will go into long-term remission.
The autologous stem cell transplant used in this research study is an investigational
      procedure that uses cyclophosphamide (chemotherapy), rabbit antithymocyte globulin (rATG) (a
      protein that kills the immune cells that are thought to be causing your disease), rituximab
      (a biologic drug that targets B cells of your immune system), and intravenous immunoglobulin
      (IVIg) (pooled IgG antibodies from plasma donors with immunomodulatory and anti-inflammatory
      effects), followed by return of your own previously collected blood stem cells (autologous
      stem cell transplant). One day of plasmapheresis will also be performed the day prior to
      admission for stem cell transplant to remove disease-causing antibodies. The ability of this
      experimental treatment to stop relapses and progression (worsening) of your NMOSD will be
      assessed.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Progression-Free Survival
time frame: 5 years
description: Disease progression defined as: 1.0-point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least six months apart and not due to a non-NMO disease process. The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability.
measure: Relapse-Free Survival
time frame: 5 years
description: Relapse defined as: Acute neurologic deterioration occurring after engraftment and lasting more than 24 hours, accompanied by objective worsening on neurological examination that are documented by a neurologist and not explained by fever, infection, stress, heat, drugs or related pseudo-exacerbation. Supportive confirmation by enhancement on MRI is preferred but not mandatory.
measure: Expanded Disability Status Scale (EDSS) Improvement
time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
description: The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. Improvement in EDSS is defined by both a 0.5 or 1.0 points sustained for more than 6 months
measure: Scripps Neurological Rating Scale (NRS) Improvement
time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
description: The NRS scale ranges from 0 to 100 in 1 point increments that represent lower levels of disability.
measure: Improvement in Quality of Life
time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
description: Measured using the short form (SF)-36 health survey.
measure: Paced Auditory Serial Addition Test (PASAT) Improvement
time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
description: The PASAT is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. Improvement measured with the 2" and 3" versions
measure: Ambulation Index Improvement
time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
description: The subject's walk of 25 feet is timed and a score from 0 to 10 is assigned based on their walk/gait and/or assistance required.
measure: 9 Hole Peg Test (9-HPT) Improvement
time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
description: The 9-HPT is a brief, standardized, quantitative test of upper extremity function. Both the dominant and non-dominant hands are tested twice, with the total time to complete the task each time recorded and then averaged.
measure: Change in NMO IgG (aquaporin-4) Antibody Titer
time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
description: Evaluation of the antibody titer, looking for a change from positive to negative.
measure: Improvement in Visual Acuity
time frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
description: A visual acuity test is an eye exam that checks how well one sees the details of a letter or symbol from a specific distance.
arm group label: Hematopoietic Stem Cell Transplantation
arm group type: Experimental
description: Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with rituximab, cyclophosphamide, mesna, rATG (rabbit), and methylprednisolone. Granulocyte-colony stimulating factor (G-CSF) and intravenous immunoglobulin (IVIg) will be administered post-transplant.
intervention type: Drug
intervention name: Rituximab
description: Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
arm group label: Hematopoietic Stem Cell Transplantation
other name: Rituxan
intervention type: Drug
intervention name: Cyclophosphamide
description: A medication used as chemotherapy and to suppress the immune system
arm group label: Hematopoietic Stem Cell Transplantation
other name: Cytoxan
intervention type: Drug
intervention name: Mesna
description: A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
arm group label: Hematopoietic Stem Cell Transplantation
other name: Mesnex
intervention type: Drug
intervention name: rATG
description: A rabbit polyclonal antibody to lymphocytes
arm group label: Hematopoietic Stem Cell Transplantation
other name: Thymoglobulin
other name: Anti-Thymocyte Globulin
intervention type: Drug
intervention name: Methylprednisolone
description: A corticosteroid medication used to suppress the immune system and decrease inflammation
arm group label: Hematopoietic Stem Cell Transplantation
other name: Solu-Medrol
other name: Depo-Medrol
intervention type: Drug
intervention name: G-CSF
description: A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
arm group label: Hematopoietic Stem Cell Transplantation
other name: Neupogen
other name: Filgrastim
other name: Granix
other name: Zarxio
intervention type: Biological
intervention name: IVIg
description: Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
arm group label: Hematopoietic Stem Cell Transplantation
other name: Bivigam
other name: Carimune Nanofiltered (NF)
other name: Gammagard
other name: Privigen
other name: Octagam
intervention type: Biological
intervention name: Autologous Stem Cells
description: Infusion of patient's own stem cells
arm group label: Hematopoietic Stem Cell Transplantation
criteria: 
gender: All
minimum age: 18 Years
maximum age: 65 Years
healthy volunteers: No
last name: Richard Burt, MD
role: Principal Investigator
affiliation: Northwestern University
facility: 
facility: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: Northwestern University
investigator full name: Richard Burt, MD
investigator title: Professor
mesh term: Neuromyelitis Optica
mesh term: Methylprednisolone
mesh term: Methylprednisolone Acetate
mesh term: Methylprednisolone Hemisuccinate
mesh term: Prednisolone
mesh term: Prednisolone acetate
mesh term: Cyclophosphamide
mesh term: Rituximab
mesh term: Thymoglobulin
mesh term: Antilymphocyte Serum
mesh term: Prednisolone hemisuccinate
mesh term: Prednisolone phosphate
sharing ipd: No